OMP 336B11
Alternative Names: GITRL-Fc; GITRL-Fc trimer; OMP-336B11Latest Information Update: 27 Sep 2019
Price :
$50 *
At a glance
- Originator OncoMed Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators; T lymphocyte stimulants; TNFRSF18 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Sep 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT03295942)
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 21 Apr 2018 Pharmacodynamics data from a preclinical functional characterisation trials presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)